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Abstract.  1 
Aims. Atrial fibrillation (AF) and heart failure (HF) are two growing epidemics that 2 
frequently co-exist. We aimed to gain insights into underlying pathophysiological pathways in 3 
HF patients with AF by comparing circulating biomarkers using pathway overrepresentation 4 
analyses. 5 
Methods and Results. From a panel of 92 biomarkers from different pathophysiological 6 
domains available in 1,620 patients with HF, we first tested which biomarkers were 7 
dysregulated in patients with HF and AF (n=648) compared with patients in sinus rhythm 8 
(n=972). Secondly, pathway overrepresentation analyses were performed to identify 9 
biological pathways linked to higher plasma concentrations of biomarkers in patients who had 10 
HF and AF. Findings were validated in an independent HF cohort (n=1,219, 38% with AF). 11 
Patient with AF and HF were older, less often women, and less often had a history of 12 
coronary artery disease compared with those in sinus rhythm. In the index cohort, 24 13 
biomarkers were upregulated in patients with AF and HF. In the validation cohort, 8 14 
biomarkers were upregulated, which all overlapped with the 24 biomarkers found in the index 15 
cohort. The strongest up-regulated biomarkers in patients with AF were spondin-1 (fold 16 
change 1.18, p=1.33x10-12), insulin-like growth factor-binding protein-1 (fold change 1.32, 17 
p=1.08x10-8), and insulin-like growth factor-binding protein-7 (fold change 1.33, p=1.35x10-18 
18). Pathway overrepresentation analyses revealed that the presence of AF was associated with 19 
activation amyloid-beta metabolic processes, amyloid-beta formation, and amyloid precursor 20 
protein catabolic processes with a remarkable consistency observed in the validation cohort.  21 
Conclusion. In two independent cohorts of patients with HF, the presence of AF was 22 
associated with activation of three pathways related to amyloid-beta. These hypothesis-23 
generating results warrant confirmation in future studies. 24 













Translational Perspective (89 words, max. 100) 1 
Using an unbiased approach, we identified and validated dysregulation of three amyloid-beta 2 
related pathways in patients who had heart failure (HF) with concomitant atrial fibrillation 3 
(AF). Amyloid-beta depositions are a hallmark of Alzheimer’s disease, but might also play a 4 
role in pathophysiological processes outside the central nervous system. Biopsy studies are 5 
needed to confirm the pathophysiological role of amyloid-beta in patients with AF and HF. 6 
Diagnostic and therapeutic implications should be investigated in the light of potential 7 
pathophysiological overlap between the three aging-related epidemics: Alzheimer’s disease, 8 














Atrial fibrillation (AF) is the most common arrhythmia in heart failure (HF) with a prevalence 2 
between 20-60% depending on the type and severity of HF.1-3 Both AF and HF are strongly 3 
associated with ageing, share many other clinical risk factors such as obesity and 4 
hypertension, and can trigger each other.2, 3 Distinct differences are observed when comparing 5 
patients with HF with and without AF. We recently showed that patients with AF and HF are 6 
older, less often have an ischemic aetiology of HF, and have a distinct biomarker profile as 7 
compared with HF patients in sinus rhythm.4, 5 Moreover, patients with AF and HF have a 8 
poorer quality of life, and worse outcome as compared with those without AF.4, 6 Pooled 9 
individual-patient data revealed that in contrast to the beneficial effects observed in patients 10 
with heart failure with a reduced ejection fraction (HFrEF) in sinus rhythm, β-blockers did not 11 
improve clinical outcomes in patients with AF and HFrEF.7 The potential lack of β-blocker 12 
efficacy suggests differences in pathophysiology between HF patients with and without AF, 13 
but the exact mechanisms remain poorly understood and understudied.7  14 
Unravelling the underlying pathophysiology of AF in HF is important since this population 15 
might respond to different therapies than HF patients without AF.8, 9 Underlying 16 
pathophysiological mechanisms can be studied by performing pathway overrepresentation 17 
analyses, a method that can identify associated pathways based on circulating biomarker 18 
profiles in specific subgroups.10, 11 Therefore, we compared patients who had HF with and 19 
without AF, studied their biomarker profiles and associated pathophysiological pathways, 20 














Patient population 2 
We performed a post-hoc study of patients enrolled in A Systems Biology Study to Tailored 3 
Treatment in Chronic Heart Failure (BIOSTAT-CHF), of which the design and primary 4 
results have been published previously.12, 13 In brief, BIOSTAT-CHF was a prospective, 5 
observational, multinational, European HF study, in which a total of 2,516 patients were 6 
included. Patients were eligible with either a left ventricular ejection fraction (LVEF) ≤40%, 7 
or plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) >2000 8 
ng/L. Another 1,738 patients with HF were included in an independent cohort from six 9 
centers in Scotland, which we have used as our validation cohort. Patients were enrolled into 10 
the validation cohort when they were diagnosed with HF and had a previous documented 11 
admission with HF requiring diuretic treatment.12 This study complies with the Declaration of 12 
Helsinki, and medical ethics committees of participating centers approved the study. All 13 
patients provided written informed consent. 14 
Definitions 15 
Patients were classified as AF when they met the following criteria: 1) a documented history 16 
of AF, and 2) AF registered on the standard 12-lead electrocardiogram (ECG) at baseline of 17 
the study. Patients were classified as having sinus rhythm when they met the following 18 
criteria: 1) no documented history of AF, and 2) sinus rhythm on the baseline ECG. Patients 19 
with a pacemaker rhythm (n=320) or unknown rhythm (n=58) were excluded from our 20 
analyses. Patients with prior episodes of AF but who were in sinus rhythm at baseline 21 
(n=197), and those without a history of AF but with AF on the baseline ECG (n=82) were 22 
excluded from our analyses, since these patients could interfere with the contrast in 23 
underlying pathophysiological pathways between the AF and sinus rhythm groups under 24 













but since subsequent analyses revealed that many biomarkers tend to fluctuate with 1 
paroxysmal episodes of AF, we chose to include HF patients with ‘permanent’ AF as 2 
compared with those who never had any previously documented episode of AF in the current 3 
analyses.4, 14 A flow chart of the selected patients is displayed in Supplementary Figure 1.  4 
Biomarkers 5 
The Olink Cardiovascular III (CVD III) panel includes 92 biomarkers from different 6 
pathophysiological domains. The Proseek Multiplex 96*96 kit of Olink Bioscience (Uppsala, 7 
Sweden) analysis service was used, which measured the 92 biomarkers in 1µl plasma 8 
samples. The reagents are based on the Proximity Extension Assay (PEA) technology, which 9 
binds 92 oligonucleotide-labeled antibody probe pairs to the target biomarker.15 For further 10 
quantification, real-time PCR was performed. Olink wizard and GenEx software were used 11 
for further data analysis. Proseek® data are presented as arbitrary units (AU) on a log2 scale 12 
(Supplementary Table 1 and 2). Complete biomarker data was available in 87% of the patients 13 
under study. 14 
Statistical analyses 15 
Normally distributed continuous variables were displayed as mean ± standard deviation, non-16 
normally distributed variables as median with the first and third quartile (Q1-Q3). Categorical 17 
variables were presented as numbers with percentages. Group comparisons were tested using 18 
Student’s t tests, Mann-Whitney U tests, or Chi-square tests where appropriate. Differences in 19 
expression of the 92 biomarkers between patients with AF versus sinus rhythm were tested 20 
using Linear Models for Microarray data analysis (Limma) software (version 3.34.9), using a 21 
log2 fold change cutoff of 0.2, and a false discovery rate <0.05 according to the Benjamini-22 
Hochberg method. The biomarkers that were upregulated in patients with AF compared to 23 
those in sinus rhythm were further studied by using pathway overrepresentation analysis. 24 













pathways in publicly available databases: Gene Ontology (GO), Reactome, and the Kyoto 1 
Encyclopedia of Genes and Genomes (KEGG), using Cytoscape (version 3.7.1) and plugin 2 
ClueGO (version 2.5.4).10, 16, 17 Multivariable logistic regression was performed to study the 3 
association between the biomarkers within pathways and AF status, adjusting for age, sex, 4 
body mass index (BMI), heart rate, a history of coronary artery disease, and renal disease. 5 
Since we were interested in underlying pathophysiological differences between patients with 6 
heart failure with a reduced/mid-range/preserved ejection fraction HFrEF/HFmrEF/HFpEF, 7 
we performed the same analyses in these subgroups. Unfortunately, these subgroups were too 8 
small to gain results with pathway overrepresentation analyses. This was still the case when 9 
we analyzed only two groups: LVEF <45% versus LVEF ≥45%. We therefore tested for 10 
interactions to determine whether the association of biomarkers and AF status was present in 11 
patients with HFrEF/HFmrEF/HFpEF by adding the interaction term to the logistic regression 12 
model, and also tested for an interaction with LVEF on a continuous scale. A separate 13 
network analysis focusing on pathophysiological differences between patients with HFpEF 14 
and HFrEF has been published previously.18 A p-value smaller than 0.1 was considered 15 
statistically significant for testing interactions. All other tests were performed two-sided, and 16 
a p-value of less than 0.05 was considered statistically significant. Statistical analyses were 17 
conducted using R, A Language and Environment for Statistical Computing, version 3.5.3 (R 18 
Foundation for Statistical Computing, Vienna, Austria).  19 
 20 
Results 21 
Index cohort 22 
Clinical characteristics 23 
Of 1,620 patients with HF enrolled, 648 (40%) had AF and 972 (60%) were in sinus rhythm. 24 













(Table 1). Fewer patients with AF had a history of coronary artery disease, but more often a 1 
history of renal disease as compared with those in sinus rhythm. Patients with AF had larger 2 
left atrial diameters, and greater interventricular and posterior wall thickness on 3 
echocardiography.  4 
Biomarker concentrations 5 
In the index cohort, 24 biomarkers were upregulated and three biomarkers were 6 
downregulated in patients with AF as compared to those in sinus rhythm (Figure 1). A 7 
volcano plot with the up- and downregulated biomarkers is presented in Figure 2A. The three 8 
biomarkers that were most significantly differentially expressed in patients with AF as 9 
compared with those in sinus rhythm were neurogenic locus notch homolog protein 3 10 
(NOTCH3, fold change 1.30, p=6.40x10-24), insulin-like growth factor binding protein-7 11 
(IGFBP7, fold change 1.33, p=1.35x10-18), and interleukin-1 receptor-like 1 (IL1RL1, fold 12 
change 1.35, p=1.75x10-16) (Supplementary Table 1).  13 
Pathway overrepresentation analyses of upregulated biomarkers 14 
Pathway overrepresentation analyses of the 24 upregulated biomarkers in the index cohort 15 
revealed seven pathways that were dysregulated specifically in patients with AF: 1) amyloid-16 
beta metabolic process, 2) amyloid-beta formation, 3) amyloid precursor protein catabolic 17 
process, 4) regulation of insulin-like growth factor (IGF) transport and uptake by IGF binding 18 
proteins, 5) embryo implantation, 6) membrane protein ectodomain proteolysis, and 7) 19 
regulation of neuroinflammatory response (Figure 3).  20 
Validation cohort 21 
Clinical characteristics 22 
The baseline characteristics of patients included in the smaller validation cohort are presented 23 













LVEF, and lower plasma concentrations of NT-proBNP as compared with patients included in 1 
the index cohort. However, similar trends were observed in patients with AF compared to 2 
those in sinus rhythm, in which patients with AF were older, less often women, had higher 3 
heart rates, and less often a history of coronary artery disease. 4 
Biomarker concentrations 5 
In the validation cohort, eight biomarkers were significantly upregulated in patients with AF, 6 
all of which overlapped with the 24 biomarkers that were found to be significantly 7 
upregulated in the index cohort (Figure 1). The eight biomarkers that were upregulated in AF 8 
patients in both HF cohorts included IGFBP7 (fold change 1.30, p=5.13x10-18), NOTCH3 9 
(fold change 1.25, p=1.44x10-17), spondin 1 (SPON1, fold change 1.18, p=1.29x10-12), 10 
IL1RL1 (fold change 1.31, p=3.44x10-11), natriuretic peptide B (fold change 1.49, p=3.78x10-11 
11), matrix metallopeptidase 2 (MMP2, fold change 1.18, p=1.25x10-9), IGFBP1 ( fold change 12 
1.26, p=6.68x10-5), and growth differentiation factor 15 (GDF15, fold change 1.16, 13 
p=1.07x10-4) (Supplementary Table 2). Low-density lipoprotein receptor (LDLR) and 14 
paraoxonase 3 (PON3) were significantly downregulated in patients with AF in both the index 15 
and the validation cohort. 16 
Pathway overrepresentation analyses of upregulated biomarkers 17 
Pathway overrepresentation analysis of the eight upregulated biomarkers in patients with AF 18 
in the validation cohort revealed three activated pathways: 1) amyloid-beta metabolic process, 19 
2) amyloid-beta formation, and 3) amyloid precursor protein catabolic process (Figure 3).  20 
Overlap index and validation cohort 21 
The three amyloid-beta-related pathways were found in both the index and validation cohort, 22 
and were related to three upregulated biomarkers in patients with AF: SPON1 (fold change 23 













p=1.35x10-18). After adjusting for the clinical covariates age, sex, body mass index, heart rate, 1 
a history of coronary artery disease, and renal disease, the concentrations of SPON-1, IGFBP-2 
1, and IGFBP-7 remained associated with the presence of AF (all p<0.001), in both the index 3 
and the validation cohort. These associations were similar among HF phenotypes 4 
(HFrEF/HFmrEF/HFpEF; p for interaction = 0.42) and across LVEF as a continuous variable 5 
(p for interaction = 0.96).  6 
 7 
Discussion 8 
We sought to identify pathophysiological pathways in HF patients with AF using pathway 9 
overrepresentation analyses. In two independent HF cohorts we found that the presence of AF 10 
was associated with amyloid-beta metabolic processes, amyloid-beta formation, and amyloid 11 
precursor protein catabolic processes. These three pathophysiological pathways were found 12 
based on higher levels of spondin-1, IGFBP1, and IGFBP7 in those with AF. In the larger 13 
index cohort, four more pathophysiological pathways were found, which were not observed in 14 
the independent validation cohort. Previous studies investigating specific phenotypes or 15 
subgroups in HF (e.g. diabetes, ischemic HF, old vs. young, and HFpEF vs. HFrEF), have not 16 
revealed any amyloid-beta-related pathways despite using the same methodology, which 17 
supports that the current findings might be specific to the presence of AF in patients with 18 
HF.10, 11, 19 19 
Individual biomarkers 20 
In the present study, the concentrations of SPON-1, IGFBP-1 and IGFBP-7 were closely 21 
linked to the three amyloid-beta-related pathways. Although IGFBP-1 and IGFBP-7 are 22 
linked to a wide range of biological processes associated with inhibition and stimulation of 23 
cell growth, the current knowledge indicates a more specific role for SPON-1.20 SPON-1 is an 24 













the heart and brain.20 The SPON-1 protein binds to the extracellular domain of amyloid 1 
precursor protein and inhibits beta-secretase cleavage of this amyloid precursor protein, a 2 
process that is strongly related to the formation of amyloid-beta depositions.21 In a large 3 
genome wide association study (GWAS) investigating the rate of cognitive decline in patients 4 
with Alzheimer’s disease, the most interesting candidate gene identified was SPON-1, since it 5 
was strongly associated with the rate of cognitive decline in two independent cohorts.22 6 
Recent studies showed that increased levels of IGFBP-7, a marker of ageing and cellular 7 
senescence, were strongly associated with increased left atrial size, and the presence of AF in 8 
patients with HF.23-25 In Framingham Heart Study participants without HF, increased levels of 9 
IGFBP1 were strongly associated with incident AF.26 In the present study, NOTCH3 was 10 
strongly upregulated in patients with AF in both cohorts. The NOTCH system communicates 11 
in multiple tissues and systems, including cell proliferation, differentiation, and apoptosis.27 In 12 
the heart specifically, NOTCH signaling has been suggested to be associated with repair of 13 
infarcted and overloaded myocardium, but this has only been investigated in a pre-clinical 14 
setting.27 The role of the NOTCH system in patients with AF and HF is yet to be elucidated.  15 
Amyloid-beta in heart failure and atrial fibrillation 16 
Cardiac amyloidosis has been reported to be associated with a high prevalence of AF in 17 
several previous studies;28-33 however prior work focused on isolated atrial amyloidosis (IAA) 18 
and transthyretin-derived amyloidosis (ATTR) – the most commonly described forms of 19 
cardiac amyloidosis in elderly patients. Our results concerned amyloid-beta depositions, 20 
which are generally acknowledged as a hallmark of Alzheimer’s disease, in which abnormal 21 
cleavage of the amyloid precursor protein leads to pathological amyloid-beta fragments, 22 
protein aggregation, and formation of extracellular plaques that can lead to degradation of 23 
neurons.34, 35 Even though Alzheimer’s disease has been traditionally considered as a brain-24 













pathophysiology, suggesting that Alzheimer’s disease might be a focal manifestation of a 1 
systemic disorder.34, 36 The epidemiological link between AF and Alzheimer’s disease was 2 
first described in 1977, followed by studies showing that younger patients with AF had an 3 
increased risk of developing all-cause dementia which could not be explained by the increased 4 
incidence of stroke alone.37-39 Since then, contradictory results have been reported, but 5 
neuropathological analyses of autopsies did reveal a higher incidence of amyloid-beta plaques 6 
and amyloid angiopathy in the brains of patients with permanent AF.40 Suggesting a unifying 7 
pathogenesis, Troncone et al. performed a cross-sectional study investigating cardiac 8 
involvement of patients with a primary diagnosis of Alzheimer’s disease as compared to age-9 
matched controls. Indeed, those with Alzheimer’s disease had increased left ventricular septal 10 
and inferolateral wall thickness on echocardiography, and expression of amyloid-beta plaques 11 
in both the heart and the brain.36  12 
Clinical relevance 13 
Even though the current study revealed pathways related to amyloid-beta specifically, 14 
considerable overlap can be observed with more commonly recognized protein-misfolding 15 
diseases that are known to affect the heart. As recently reviewed, cardiac involvement has 16 
predominantly been reported in IAA, light chain (AL) and ATTR amyloidosis, but may occur 17 
in other types of amyloidosis, with cardiac arrhythmias, especially atrial fibrillation, as 18 
common presenting clinical features.41 The consistency of cardiac clinical presentations 19 
among the various types of amyloidosis, despite differences in involved proteins (e.g. ANP 20 
versus AL versus ATTR), suggest common cardiac effects which may also plausibly apply to 21 
amyloid-beta deposition.42 Notably, the emergence of promising new treatment options for 22 
ATTR amyloidosis has raised awareness of the importance of screening for amyloidosis in 23 
patients with suggestive clinical features.43-45 Whether similar mechanistic approaches can be 24 













Strengths and Limitations 1 
To our knowledge, there have been no previous studies investigating underlying 2 
pathophysiological processes using pathway overrepresentation in patients with AF and HF. 3 
Therefore, our study adds to the limited understanding of the underlying pathophysiological 4 
mechanisms of AF in patients with HF. The greatest strength of the current study is that we 5 
were able to validate our results in an independent HF cohort with clear definitions, and that 6 
the pathway overrepresentation analysis was based on a large number of measured plasma 7 
biomarkers.  8 
A limitation of this study is that the findings are based on post-hoc analyses. Unfortunately, 9 
we did not have direct biopsy evidence of cardiac/atrial amyloid-beta involvement which are 10 
pivotal to confirm the cardiac amyloid-beta hypothesis. Future research in cases (patients with 11 
AF+HF) and controls (patients in sinus rhythm with and without HF) with markers derived 12 
from atrial tissue will provide more direct insights into our hypothesis.46 Another limitation 13 
concerns the selected biomarker panel, which did cover many pathophysiological domains, 14 
but was primarily a cardiovascular disease-related biomarker panel. The number of 15 
significantly upregulated biomarkers was higher in the index cohort than in the validation 16 
cohort, which resulted in more associated pathophysiological processes in the index cohort 17 
than in the validation cohort. This could be the consequence of the larger number of patients 18 
included in the index cohort, the different inclusion criteria of patients that were used for the 19 
two independent cohorts, or the different regions of inclusion of the study participants (11 20 
European counties versus six centers in Scotland). The use of amiodarone was higher in the 21 
index cohort compared with the validation cohort. However, despite these differences 22 
between the two cohorts, all upregulated biomarkers and pathways found in the validation 23 
cohort overlapped with those found in the index cohort. The HFrEF, HFmrEF and HFpEF 24 













analyses. There was, however, no interaction between the amyloid-beta-related biomarkers 1 
and the HF subgroups, suggesting a pathophysiological role of amyloid-beta in HF patients 2 
across the full LVEF spectrum. Not all (combinations of) biomarkers were annotated by the 3 
publicly available databases even though these biomarkers were deemed to be significantly 4 
up- or downregulated in our analyses (e.g. NOTCH3 and IL1RL1), since the content of these 5 
databases is based on what is currently known about these biomarkers. Therefore, the results 6 
of the current pathway overrepresentation analyses might change over time, when the 7 
knowledge on the (combination of) biomarkers has increased. The current findings might 8 
reflect underlying pathophysiological processes specific to elderly patients with AF and HF, 9 
since the mean age of these patients was 72 and 75 years in the two cohorts respectively. The 10 
number of women included in the cohorts was limited (n=462 [index] and n=439 [validation], 11 
32%) and mainly comprised postmenopausal women. Even though we have attempted to 12 
define the AF and sinus rhythm group mutually exclusive, it is possible that patients with 13 
asymptomatic paroxysmal AF were misclassified. Based on the current definition, we may 14 
have predominantly included patients with persistent/permanent AF and less patients with 15 
paroxysmal AF. Moreover, we do not have data on the duration of AF since no continues 16 
rhythm monitoring was incorporated in the study protocol, which might have influenced the 17 
biomarker concentrations. Unfortunately, we also do not have information on cognitive 18 
function, other neurologic diseases, nor information on systemic or cardiac amyloidosis of 19 
patients enrolled in BIOSTAT-CHF, which could have strengthened our hypothesis linking 20 
AF – HF to Alzheimer’s disease and/or amyloidosis. As with all cross-sectional studies, we 21 
cannot prove causality.  22 
Conclusion  23 
In two independent cohorts of patients with HF, the presence of AF was associated with 24 













catabolic processes, based on higher levels of spondin-1, IGFBP1, and IGFBP7 in those with 1 
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Figure Legends. 1 
Figure 1. Venn diagram displaying the number of significantly upregulated and 2 
downregulated biomarkers in patients with atrial fibrillation versus sinus rhythm in the index 3 
(n=1,620) and validation cohort (n=1,219) of BIOSTAT-CHF. 4 
Figure 2. Volcano plots of differential biomarker expression in patients with atrial fibrillation 5 
versus sinus rhythm in the index (A, n=1,620) and validation cohort (B, n=1,219) of 6 
BIOSTAT-CHF. Y-axis = significance, x-axis = effect size (positive = up-regulated, negative 7 
= down-regulated), labelled biomarkers are significantly differentially expressed proteins. 8 
Figure 3. Results of pathway overrepresentation analyses of patients with atrial fibrillation 9 
versus sinus rhythm in the index cohort (A [n=1,620]) and the validation cohort (B [n=1,219) 10 
of BIOSTAT-CHF. The nodes in blue represent the 24 biomarkers that were significantly 11 
upregulated in patients with atrial fibrillation as compared with those in sinus rhythm in the 12 
index cohort (A), and 8 biomarkers that were significantly upregulated in these patients in the 13 
validation cohort (B). The nodes in red reveal the overrepresented pathways of these 14 
biomarkers. Based on current knowledge, the blue nodes below the figures are biomarkers 15 













Table 1. Baseline characteristics of patients included in the index cohort. 1 
 Atrial fibrillation Sinus rhythm P-value 
 n=648 (40%) n=972 (60%)  
Clinical    
   Age (years) 72 ± 10 65 ± 13 <0.001 
   Women (%) 164 (25) 298 (31) 0.02 
   BMI (kg/m2) 28 ± 6 27 ± 6 <0.001 
   NYHA Class I/II/III/IV (%) 9/50/37/4 12/53/32/4 0.07 
   Systolic blood pressure (mmHg) 125 ± 21 126 ± 23 0.43 
   Diastolic blood pressure (mmHg) 76 ± 13 75 ± 14 0.23 
   Heart rate (b.p.m.) 91 ± 24 80 ± 18 <0.001 
   Smoking   <0.001 
       Never 270 (42) 322 (33)  
       Past 318 (49) 450 (46)  
       Current 58 (9) 200 (21)  
History of (%)    
   Coronary artery disease* 244 (38) 448 (46) 0.001 
   Valvular surgery 71 (11) 31 (3) <0.001 
   Stroke 72 (11) 71 (7) 0.011 
   Peripheral artery disease 69 (11) 88 (9) 0.33 
   Hypertension 419 (65) 597 (61) 0.20 
   Diabetes 210 (32) 308 (32) 0.80 
   COPD 116 (18) 140 (14)  0.07 
   Renal disease 213 (33) 213 (22) <0.001 
Physical examination (%)    
   Rales  356 (56) 486 (52) 0.10 
   Oedema  393 (70) 399 (50) <0.001 
   Hepatomegaly 113 (18) 106 (11) <0.001 
KCCQ – Quality of Life    
   Functional status score 43 [25, 64] 54 [34, 75] <0.001 
   Clinical summary score 41 [24, 61] 50 [32, 71] <0.001 
   Overall score 41 [26, 61] 51 [34, 70] <0.001 













   NT-proBNP (ng/L) 3430 [1872, 6387] 2293 [925, 5347] <0.001 
   Haemoglobin (g/L) 13.3 [11.9, 14.6] 13.4 [12.1, 16.6] 0.28 
   Creatinine (μmol/L) 104 [88, 131] 97 [80, 121] <0.001 
Echocardiographic data    
   LVEF, % 33 ± 12 29 ± 10 <0.001 
   Left atrial diameter, mm 50 ± 8 46 ± 8 <0.001 
   Interventricular wall thickness, mm 11 ± 2 10 ± 2 <0.001 
   Posterior wall thickness, mm 11 ± 2 10 ± 2 <0.001 
Medication at baseline (%)    
   ACE i or ARB 440 (68) 726 (75) 0.003 
   β blocker 523 (81) 810 (83) 0.20 
   MRA 318 (49) 516 (53) 0.13 
   Diuretics 648 (100) 971 (100) 1.00 
   Amiodarone 81 (13) 110 (11) 0.52 
   Digoxin 246 (38) 60 (6) <0.001 
   Verapamil/diltiazem 22 (3) 7 (1) <0.001 
   Class 1c antiarrhythmic drugs  2 (1) 2 (1) 1.00 
   Ivabradine 0 (0) 23 (2) <0.001 
   Vitamin K antagonist 461 (71) 130 (13) <0.001 
   Direct oral anticoagulants 7 (1) 0 (0) 0.004 
 1 
*Coronary artery disease: previous myocardial infarction, percutaneous coronary intervention (PCI) and/or coronary artery 2 
bypass graft (CABG). BMI=body mass index, NYHA=New York Heart Association, LVEF=left ventricular ejection fraction, 3 
BP = blood pressure, COPD=chronic obstructive pulmonary disease, KCCQ=Kansas City Cardiomyopathy Questionnaire, 4 
NT-proBNP=N-terminal pro-B-type natriuretic peptide, ACE i=angiotensin converting enzyme inhibitor, ARB=angiotensin 5 
receptor blocker, MRA=mineralocorticoid receptor antagonist. P-values for group comparisons were tested using Student’s t 6 
tests, Mann-Whitney U tests, or Chi-square tests where appropriate. 7 













Table 2. Baseline characteristics of patients included in the validation cohort.  1 
 Atrial fibrillation Sinus rhythm P-value 
 n=468 (38%) n=751 (62%)  
Clinical    
   Age (years) 75 ± 10 72 ± 11 <0.001 
   Women (%) 148 (32) 291 (39) 0.01 
   BMI (kg/m2) 29 ± 6 29 ± 6 0.13 
   NYHA Class I/II/III/IV (%) 0/39/46/14 2/42/44/13 0.22 
   Systolic blood pressure (mmHg) 126 ± 21 127 ± 23 0.38 
   Diastolic blood pressure (mmHg) 72 ± 15 68 ± 12 <0.001 
   Heart rate (b.p.m.) 87 ± 27 72 ± 18 <0.001 
   Smoking   <0.001 
       Never 275 (59) 358 (48)  
       Past 148 (32) 279 (37)  
       Current 43 (9) 110 (15)  
History of (%)    
   Coronary artery disease* 194 (42) 462 (62) <0.001 
   Valvular surgery 39 (8) 39 (5) 0.04 
   Stroke 105 (23) 105 (14) <0.001 
   Peripheral artery disease 96 (21) 160 (22) 0.79 
   Hypertension 274 (59) 434 (58) 0.80 
   Diabetes 149 (32) 225 (30) 0.53 
   COPD 83 (18) 135 (18) 0.99 
   Renal disease 220 (47) 312 (42) 0.11 
Physical examination (%)    
   Rales  219 (49) 301 (42) 0.02 
   Oedema  290 (68) 385 (57) 0.001 
   Hepatomegaly 20 (5) 23 (3) 0.36 
KCCQ – Quality of Life    
   Functional status score 45 [25, 65] 46 [27, 71] 0.05 
   Clinical summary score 41 [25, 65] 45 [26, 70] 0.07 
   Overall score 42 [30, 60] 45 [30, 68] 0.03 
Laboratory data    
   NT-proBNP (ng/L) 2105 [1045, 4204] 872 [311, 2807] <0.001 
   Haemoglobin (g/L) 13.5 [12.1, 14.7] 13.1 [11.7, 14.3] 0.004 
   Creatinine (μmol/L) 98 [82, 123] 95 [77, 121] 0.04 
Echocardiographic data    
   LVEF, % 43 ± 13 41 ± 13 0.03 
   Left atrial diameter, mm 48 ± 7 43 ± 7 <0.001 
   Interventricular wall thickness, mm 13 ± 3 12 ±  4 0.29 
   Posterior wall thickness, mm 12 ± 4 11 ± 5 0.54 
Medication at baseline (%)    













   β blocker 339 (72) 540 (72) 0.89 
   MRA 144 (31) 229 (31) 0.97 
   Diuretics 457 (98) 746 (99) 0.02 
   Amiodarone 12 (3) 27 (4) 0.41 
   Digoxin 193 (41) 12 (2) <0.001 
   Verapamil/diltiazem 18 (4) 13 (2) 0.036 
   Class 1c antiarrhythmic drugs  0 (0) 0 (0) 1.00 
   Ivabradine 1 (1) 33 (4) <0.001 
   Vitamin K antagonist 327 (70) 87 (12) <0.001 
   Direct oral anticoagulants 22 (5) 6 (1) <0.001 
 1 
*Coronary artery disease: previous myocardial infarction, percutaneous coronary intervention (PCI) and/or coronary artery 2 
bypass graft (CABG). BMI=body mass index, NYHA=New York Heart Association, LVEF=left ventricular ejection fraction, 3 
BP = blood pressure, COPD=chronic obstructive pulmonary disease, KCCQ=Kansas City Cardiomyopathy Questionnaire, 4 
NT-proBNP=N-terminal pro-B-type natriuretic peptide, ACE i=angiotensin converting enzyme inhibitor, ARB=angiotensin 5 
receptor blocker, MRA=mineralocorticoid receptor antagonist. P-values for group comparisons were tested using Student’s t 6 













Figure 1. Venn diagram displaying the number of significantly upregulated and downregulated biomarkers in patients with atrial fibrillation versus sinus 















Figure 2. Volcano plots of differential biomarker expression in patients with atrial fibrillation versus sinus rhythm in the index (A, n=1,620) and validation 
cohort (B, n=1,219) of BIOSTAT-CHF. Y-axis = significance, x-axis = effect size (positive = up-regulated, negative = down-regulated), labelled biomarkers 
are significantly differentially expressed proteins. 



























Figure 3. Results of pathway overrepresentation analyses of patients with atrial fibrillation versus sinus rhythm in the index cohort (A [n=1,620]) and the 
validation cohort (B [n=1,219]) of BIOSTAT-CHF. The nodes in blue represent the 24 biomarkers that were significantly upregulated in patients with atrial 
fibrillation as compared with those in sinus rhythm in the index cohort (A), and 8 biomarkers that were significantly upregulated in these patients in the 
validation cohort (B). The nodes in red reveal the overrepresented pathways of these biomarkers. Based on current knowledge, the blue nodes below the 
figures are biomarkers that were not found to be overrepresented in a specific biological pathway. 


























Abbreviations: SPON-1=spondin 1, IGFBP-1=insulin like growth factor binding protein 1, IGFBP-7=insulin like growth factor binding protein 7, MMP-3=matrix metallopeptidase 3, 1 
TNFRSF1B= TNF receptor superfamily member 1B, TIMP-4= Metalloproteinase inhibitor 4, SPP-1= secreted phosphoprotein 1, MMP-2=matrix metallopeptidase 2, IGFBP-2= insulin like 2 
growth factor binding protein 2, CPA1= carboxypeptidase A1, CPB1= carboxypeptidase B1, CSTB= cystatin B, FABP4= Fatty acid-binding protein, adipocyte, HSPG2= heparan sulfate 3 
proteoglycan 2, MB= Myoglobin, NOTCH3= Neurogenic locus notch homolog protein 3, NPPB=natriuretic peptide B, PLAT= plasminogen activator, tissue type, PLAUR= plasminogen 4 
activator, urokinase receptor, TFF3= trefoil factor 3, CHI3L1= chitinase 3 like 1, TNFRSF1A= TNF receptor superfamily member 1A, IL1RL-1=interleukin 1 receptor like 1, GDF-15=growth 5 
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